UY30758A1 - Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones. - Google Patents
Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones.Info
- Publication number
- UY30758A1 UY30758A1 UY30758A UY30758A UY30758A1 UY 30758 A1 UY30758 A1 UY 30758A1 UY 30758 A UY30758 A UY 30758A UY 30758 A UY30758 A UY 30758A UY 30758 A1 UY30758 A1 UY 30758A1
- Authority
- UY
- Uruguay
- Prior art keywords
- crystalline forms
- pharmaceutical compositions
- amino
- tetrafluorofenoxi
- oxopentanoico
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical compound CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000005950 Oxamyl Substances 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a formas cristalinas del acido ( 3S)-3[N-(N?? -(2-tercbutifenil)oxamil)alaninil]amino-5-(-2`,3??,5??,6??-tetrafluorofenoxil)-4-oxopentanoico (vease la formula I ). La invencion se refiere además a composiciones farmacéuticas que comprenden dichas formas cristalinas y a la utilizacion de dichas composiciones farmacéuticas y dichas formas cristalinas en el tratamiento de varias afecciones particularmente en el tratamiento de la fibrosis hepática.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86874806P | 2006-12-06 | 2006-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30758A1 true UY30758A1 (es) | 2008-07-31 |
Family
ID=39205161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY30758A UY30758A1 (es) | 2006-12-06 | 2007-12-04 | Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7692038B2 (es) |
| EP (1) | EP2091910B1 (es) |
| JP (1) | JP5495787B2 (es) |
| KR (1) | KR101125932B1 (es) |
| CN (3) | CN101573328B (es) |
| AR (1) | AR064809A1 (es) |
| AU (1) | AU2007330478B2 (es) |
| CA (1) | CA2669849C (es) |
| CL (1) | CL2007003491A1 (es) |
| DK (1) | DK2091910T3 (es) |
| ES (1) | ES2524021T3 (es) |
| HK (3) | HK1138567A1 (es) |
| HN (1) | HN2007000536A (es) |
| IL (1) | IL198732A (es) |
| MX (1) | MX2009006055A (es) |
| NO (1) | NO338908B1 (es) |
| PA (1) | PA8759501A1 (es) |
| PE (1) | PE20081251A1 (es) |
| PL (1) | PL2091910T3 (es) |
| PT (1) | PT2091910E (es) |
| TW (1) | TWI345466B (es) |
| UY (1) | UY30758A1 (es) |
| WO (1) | WO2008068615A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59494B1 (sr) * | 2010-02-12 | 2019-12-31 | Pfizer | Soli i polimorfi 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4, 3-cd]indol-6-ona |
| CN103113405B (zh) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | 苯磷硫胺多晶型体、制备方法及其应用 |
| NZ723859A (en) * | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| MX2016014731A (es) | 2014-05-12 | 2017-05-04 | Conatus Pharmaceuticals Inc | Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa. |
| EP3191461B1 (en) * | 2014-09-08 | 2021-11-03 | Pfizer Inc. | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
| NZ772411A (en) | 2015-01-30 | 2022-05-27 | Vertex Pharma | Crystalline forms of c21h22ci2n4o2 |
| US20180044375A1 (en) | 2015-03-06 | 2018-02-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
| CN105017061B (zh) * | 2015-07-07 | 2017-03-29 | 苏州富士莱医药股份有限公司 | 一种恩利卡生的合成方法 |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| WO2017117478A1 (en) | 2015-12-31 | 2017-07-06 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
| RU2019113150A (ru) | 2016-10-05 | 2020-11-06 | Новартис Аг | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения |
| WO2018133870A1 (zh) * | 2017-01-23 | 2018-07-26 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
| WO2018172950A1 (en) * | 2017-03-23 | 2018-09-27 | Novartis Ag | Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate |
| JP7295025B2 (ja) * | 2017-03-30 | 2023-06-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態 |
| AR114251A1 (es) * | 2018-02-13 | 2020-08-12 | Syngenta Participations Ag | Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida |
| US11447497B2 (en) | 2018-06-29 | 2022-09-20 | Histogen, Inc. | (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
| TW202100506A (zh) | 2019-03-07 | 2021-01-01 | 美商柯納特斯製藥公司 | 半胱天冬酶(caspase)抑制劑及其使用方法 |
| CN111351780A (zh) * | 2019-12-29 | 2020-06-30 | 中船重工（邯郸）派瑞特种气体有限公司 | 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0526171B1 (en) * | 1991-07-30 | 1997-03-05 | Ajinomoto Co., Inc. | Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them |
| ATE157349T1 (de) * | 1993-05-12 | 1997-09-15 | Heumann Pharma Gmbh & Co | Stabile und kristalline form von bezafibrat |
| US7053056B2 (en) | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6544951B2 (en) * | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6197750B1 (en) | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| GB9923933D0 (en) * | 1999-10-08 | 1999-12-08 | Smithkline Beecham Lab | Novel pharmaceutical |
| DE60225841T2 (de) * | 2001-12-11 | 2009-05-14 | Kyorin Pharmaceutical Co., Ltd. | Neue stabile kristalle substituierter phenylpropionsäurederivate und verfahren zu deren herstellung |
| CA2614622A1 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
-
2007
- 2007-12-03 ES ES07859033.8T patent/ES2524021T3/es active Active
- 2007-12-03 KR KR1020097011692A patent/KR101125932B1/ko active IP Right Grant
- 2007-12-03 CN CN200780045311.8A patent/CN101573328B/zh active Active
- 2007-12-03 DK DK07859033.8T patent/DK2091910T3/en active
- 2007-12-03 PT PT78590338T patent/PT2091910E/pt unknown
- 2007-12-03 CN CN201410058519.5A patent/CN103951583B/zh active Active
- 2007-12-03 CN CN201410057544.1A patent/CN103923169B/zh not_active Expired - Fee Related
- 2007-12-03 JP JP2009539823A patent/JP5495787B2/ja active Active
- 2007-12-03 CA CA2669849A patent/CA2669849C/en active Active
- 2007-12-03 WO PCT/IB2007/003900 patent/WO2008068615A1/en active Application Filing
- 2007-12-03 MX MX2009006055A patent/MX2009006055A/es active IP Right Grant
- 2007-12-03 AU AU2007330478A patent/AU2007330478B2/en active Active
- 2007-12-03 PL PL07859033T patent/PL2091910T3/pl unknown
- 2007-12-03 EP EP07859033.8A patent/EP2091910B1/en active Active
- 2007-12-04 HN HN2007000536A patent/HN2007000536A/es unknown
- 2007-12-04 PA PA20078759501A patent/PA8759501A1/es unknown
- 2007-12-04 CL CL200703491A patent/CL2007003491A1/es unknown
- 2007-12-04 UY UY30758A patent/UY30758A1/es not_active Application Discontinuation
- 2007-12-05 AR ARP070105447A patent/AR064809A1/es not_active Application Discontinuation
- 2007-12-05 TW TW096146304A patent/TWI345466B/zh active
- 2007-12-05 PE PE2007001720A patent/PE20081251A1/es not_active Application Discontinuation
- 2007-12-06 US US11/951,801 patent/US7692038B2/en active Active
-
2009
- 2009-05-13 IL IL198732A patent/IL198732A/en active IP Right Grant
- 2009-05-14 NO NO20091892A patent/NO338908B1/no not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104322.9A patent/HK1138567A1/xx not_active IP Right Cessation
-
2015
- 2015-01-07 HK HK15100168.9A patent/HK1199885A1/xx unknown
- 2015-01-23 HK HK15100810.1A patent/HK1200440A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30758A1 (es) | Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones. | |
| RS52306B (en) | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE CO-CRYSTALS | |
| TW200716568A (en) | 1H-quinazoline-2,4-diones | |
| NI200600240A (es) | FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| PA8629201A1 (es) | Polimorfo cristalino de acetato de bazedoxifeno | |
| SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
| BRPI0518301A2 (pt) | inseticidas | |
| BR0311693A (pt) | Sal de formato de o-desmetil-venlafaxina | |
| BRPI0913457A2 (pt) | "composto, composição farmacêutica, e, uso do composto" | |
| MY153763A (en) | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | |
| BRPI0408347A (pt) | derivados de pirimidina | |
| ECSP066376A (es) | FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| ATE540041T1 (de) | Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon | |
| ECSP066715A (es) | ||
| NO20090175L (no) | Stabile laquinimod sammensetninger | |
| TW200642700A (en) | Chemically defined stabiliser | |
| CR8615A (es) | Polimorfo cristalino de un acetato de bazedoxifeno | |
| BRPI0411528A (pt) | uso de isomalte como prebiótico | |
| DE602008000754D1 (de) | Tropanverbindungen | |
| UY30274A1 (es) | Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones | |
| WO2006114401A3 (en) | Novel cyclic amines | |
| ATE440833T1 (de) | Antithrombotische diamide | |
| BRPI0620229A8 (pt) | formulação | |
| TW200738627A (en) | Trialkylsilyl-indoles | |
| DK1583756T3 (da) | Thiophencarboxamider som inhibitorer af enzymet IKK-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20191011 |